Article

A Potential Role for F-18 FDG PET/CT in Evaluation and Management of Fibrosing Mediastinitis.

PET Imaging Center, Biomedical Research Foundation of Northwest Louisiana 71105, USA.
Clinical Nuclear Medicine (Impact Factor: 2.96). 10/2007; 32(9):703-6. DOI: 10.1097/RLU.0b013e318125035b
Source: PubMed

ABSTRACT Fibrosing mediastinitis is an uncommon benign disorder, and its pathogenesis and management remain unclear. Conventional imaging techniques (chest radiographs, CT, MRI) may suggest its diagnosis but are frequently nonspecific, and it frequently mimics a malignant process by presenting as a mediastinal mass without calcifications, encasing, and infiltrating adjacent mediastinal structures, and showing an overall aggressive behavior. The value of FDG PET imaging in this entity remains largely unknown with only a few case reports in the literature, and often, biopsy is necessary for definitive diagnosis. We report a case of biopsy proven fibrosing mediastinitis highlighting the utility of PET in the evaluation and management of the disease.

0 Bookmarks
 · 
115 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Fibrosing mediastinitis (FM), also known as granulomatous or sclerosing mediastinitis, is an uncommon but serious cause of chest symptoms. Due to an infectious or inflammatory challenge, production of collagen occurs in the confined space of the mediastinum. Collagen formation leads to compression of vital structures, resulting in cough, chest pain and dyspnea. The majority of cases of FM occur as a result of prior exposure to Histoplasma capsulatum. The following is a case of a previously healthy young woman who presented with a 3-month history of cough, chest pain and trouble breathing, and was subsequently found to have fibrosing mediastinitis. Fibrosing mediastinitis should be considered in the differential diagnosis of cough, chest pain and dyspnea, primarily when findings such as increased venous pressure are present on physical exam and hilar abnormalities are seen on chest radiograph. Clinical presentation, diagnosis and management of fibrosing mediastinitis are discussed.
    Journal of General Internal Medicine 06/2013; · 3.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE: The purpose of this article is to review and illustrate the pathogenesis, natural history, imaging features, and treatment of granulomatous fibrosing mediastinitis. CONCLUSION: Granulomatous fibrosing mediastinitis is an infiltrative disorder characterized by encasement of the mediastinal viscera; in most cases in the United States, it represents an idiosyncratic immune response to histoplasma. Familiarity with the various imaging features of fibrosing mediastinitis is important for prompt and accurate diagnosis as well as for planning and guiding surgical and less-invasive treatments.
    American Journal of Roentgenology 08/2012; 199(2):319-27. · 2.90 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die fibrosierende Mediastinitis oder Mediastinalfibrose ist eine seltene Erkrankung. Sie tritt überwiegend in Verbindung mit einer Histoplasma-capsulatum-Infektion auf. In unseren Breitengraden lässt sich eine spezifische Ursache häufig nicht definieren. Symptome resultieren überwiegend aus der Kompression der zentralen Atemwege und der großen Gefäße wie der V. cava superior oder der Pulmonalarterie. Die pathologisch-histologische Diagnosesicherung erfolgt durch Gewebe aus bronchoskopischen Untersuchungen oder – häufiger – aus chirurgischen Eingriffen wie der Mediastinoskopie. Eine allgemein akzeptierte, wirksame Pharmakotherapie existiert nicht. Üblicherweise wird ein Therapieversuch mit systemischen Kortikosteroiden durchgeführt. Im Management der Erkrankung stehen die interventionellen Maßnahmen wie z.B. Stentimplantationen in Atemwege oder Gefäße im Vordergrund. Mediastinal fibrosis is a rare disease which mostly occurs in combination with Histoplasma capsulatum infections. In European latitudes a specific cause can often not be defined. Symptoms mostly result from compression of the central airways and large vessels such as the superior vena cava or pulmonary artery. The histopathologic diagnosis is made on tissue from bronchoscopic examinations or more commonly from surgical interventions such as mediastinoscopy. A generally accepted effective pharmacotherapy does not exist and therapy is normally attempted with systemic corticosteroids. Interventional measures, such as stent implantation in the airways or vessels, have priority in the management of the disease.
    Der Pneumologe 01/2009; 6(3):161-164.